NUVASIVE, INC.
SAN DIEGO, CA

The materials on this website are for your general educational information only. Information you read on this website cannot replace the relationship that you have with your healthcare professional. We do not practice medicine or provide medical services or advice as a part of this website. You should always talk to your healthcare professional for diagnosis and treatment. The NuVasive approach to Minimally Invasive Surgery (MIS) is a new surgical platform called Maximum Access Surgery (MAS®), because it delivers the benefit of traditional surgery and the reduced trauma of MIS. By comparison, traditional “open” spine surgery often requires an incision that is at least 4-6 inches, whereas MAS technology typically requires an incision that is just a couple of inches. At NuVasive, we are best known for developing the XLIF® procedure, a minimally disruptive procedure that allows spine surgeons to have direct access to the intervertebral disc space (the “joint” of the spine) from the side of the body, as opposed to the front or back. The XLIF procedure is just one of many innovative NuVasive procedures which have redefined spine surgery and beyond. Our line of products and surgical procedures at NuVasive are complemented by state-of-the-art surgeon education programs and training. Our support includes online learning, live clinical observation, case support and peer education. Hundreds of surgeons are trained at our hands-on cadaver labs every year. NuVasive has a distinct performance culture where its Shareowners are the critical drivers of the company’s success. Employees are called Shareowners, because that’s exactly what they are—owners who embrace the culture of teamwork, innovation, and high expectations. This culture creates a unique edge that influences how we conduct business and drives Shareowners to make decisions. NuVasive is not only focused on developing innovative technology, but also on providing support to people suffering from back pain. The Better Way Back® program is dedicated to building a community that provides hope and support to patients suffering from chronic back, leg, or neck pain. This program is committed to educating patients and clinicians about surgical and non-surgical treatment options. NuVasive launched the NuVasive Spine Foundation™ (NSF) in 2009 with a mission to provide medical equipment, surgical support, and necessary funds to those in need of life-saving spine surgery around the world. The NSF leads medical mission trips and provides aid to those who suffer from chronic back and leg pain, which embodies our commitment to an 'Attitude of Gratitude'. The NuVasive approach to Minimally Invasive Surgery (MIS) is a new surgical platform called Maximum Access Surgery (MAS®), because it delivers the benefit of traditional surgery and the reduced trauma of MIS. By comparison, traditional “open” spine surgery often requires an incision that is at least 4-6 inches, whereas MAS technology typically requires an incision that is just a couple of inches. At NuVasive, we are best known for developing the XLIF® procedure, a minimally disruptive procedure that allows spine surgeons to have direct access to the intervertebral disc space (the “joint” of the spine) from the side of the body, as opposed to the front or back. The XLIF procedure is just one of many innovative NuVasive procedures which have redefined spine surgery and beyond. Our line of products and surgical procedures at NuVasive are complemented by state-of-the-art surgeon education programs and training. Our support includes online learning, live clinical observation, case support and peer education. Hundreds of surgeons are trained at our hands-on cadaver labs every year. NuVasive has a distinct performance culture where its Shareowners are the critical drivers of the company’s success. Employees are called Shareowners, because that’s exactly what they are—owners who embrace the culture of teamwork, innovation, and high expectations. This culture creates a unique edge that influences how we conduct business and drives Shareowners to make decisions. NuVasive is not only focused on developing innovative technology, but also on providing support to people suffering from back pain. The Better Way Back® program is dedicated to building a community that provides hope and support to patients suffering from chronic back, leg, or neck pain. This program is committed to educating patients and clinicians about surgical and non-surgical treatment options. NuVasive launched the NuVasive Spine Foundation™ (NSF) in 2009 with a mission to provide medical equipment, surgical support, and necessary funds to those in need of life-saving spine surgery around the world. The NSF leads medical mission trips and provides aid to those who suffer from chronic back and leg pain, which embodies our commitment to an 'Attitude of Gratitude'. has served as a member of our Board of Directors since June 2015. From July 2002 to December 2013, Ms. Capps served as the Chief Financial Officer of DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management. Prior to joining DJO Global, she served as the Chief Financial Officer of several other public and private companies. Earlier in her career, she served as a senior audit and accounting professional at Ernst & Young LLP. Ms. Capps is a member of the Senior Advisory Board of Consonance Capital Partners and serves on the board of its portfolio company, Enclara Pharmacia. She also serves on the board of directors and as chair of the audit committees of Otonomy, Inc. and Connecture, Inc. Ms. Capps is a California Certified Public Accountant and was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. She earned a bachelor’s degree in business administration/accounting from San Diego State University. John A. DeFord, Ph.D. has served as a member of our Board since February 2018. Dr. DeFord is currently the Senior Vice President, Research and Development, Interventional Segment for Becton, Dickinson and Company, a global medical technology company. Dr. DeFord joined Becton Dickinson following its December 2017 acquisition of C.R. Bard, Inc., where he had served as Senior Vice President, Science, Technology and Clinical Affairs since June 2007. Dr. DeFord joined Bard in 2004, and served in science and technology roles of increasing responsibility since that time. Prior to joining Bard, Dr. DeFord was Managing Director of Early Stage Partners LP, a venture capital fund. Prior to joining Early Stage Partners, Dr. DeFord was President and CEO of Cook Incorporated, a privately held medical device manufacturer. Dr. DeFord is a graduate of Purdue University with a B.S. and M.S. in Electrical Engineering and a Ph.D. in Electrical/Biomedical Engineering.